drugset / Trial / NCT02163278

A Multiple Ascending Dose Phase I Study of DBPR108 in Healthy Male Subjects

NCT02163278

Phase 1 Completed 32 enrolled National Health Research Institutes, Taiwan
RandomizedSingle-groupTriple-blindTreatment

Summary

The study is being performed to assess the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) properties of multiple oral doses of DBPR108 in healthy male subjects.

Timeline

Start
2014-06
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject DBPR108 Small molecule 25 mg Oral
Subject DBPR108 Small molecule 600 mg Oral